Santarus, Inc. – Trademark Portfolio

Entity Type: 03

Santarus, Inc. holds 48 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 45 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include UCERIS, ZEGERID, FENOGLIDE, and ZEGERID OTC. The owner is based in San Diego, CA.

Suite 400

3721 Valley Centre Drive

San Diego, CA 92130

48 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (48 results)

Trademark Classifications

Santarus, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (45 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

44
Medical Services (3 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Santarus, Inc. have?

Santarus, Inc. has 48 U.S. trademarks filed with the USPTO. Of these, 5 registered, 38 abandoned, 5 cancelled.

What trademark classes does Santarus, Inc. file in?

Santarus, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Santarus, Inc.'s most well-known trademarks?

Santarus, Inc.'s registered trademark portfolio includes well-known marks such as UCERIS, ZEGERID, FENOGLIDE, and ZEGERID OTC. These are among 5 currently registered trademarks in the portfolio.

What is Santarus, Inc.'s trademark registration success rate?

Santarus, Inc. has a 10% trademark registration rate, with 5 out of 48 resolved applications resulting in successful registration. Currently, 0 applications are pending review.